Active ingredientBerubicinCat. No. P-B057-001CAS 677017-23-1Family · Pharmaceutical analytical standards
Berubicin
A synthetic anthracycline studied as a chemotherapy for glioblastoma, the most common malignant brain tumour, which went on to reach phase II clinical trials. This family brings together the active ingredient.
Did you know?It was designed by Waldemar Priebe at the University of Texas MD Anderson Cancer Center, who modified the anthracycline structure so that it could cross the blood-brain barrier that protects the brain.
Go to the active ingredient →Active ingredientBerubicinCat. No. P-B057-001CAS 677017-23-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.